Belize vs Nicaragua: Statin use vs. average non-HDL cholesterol levels
Belize
3.4
in 2018
Nicaragua
3.4
in 2018
Belize rank
75th
Nicaragua rank
75th
Statin use vs. average non-HDL cholesterol levels over time
- Belize
- Nicaragua
How they compare
Belize currently reports 3.4 against 3.4 in Nicaragua, a difference of 0.
Across all 39 years both countries report, Nicaragua has been ahead every year.
Belize ranks 75th and Nicaragua ranks 75th of 191 countries.
Nicaragua has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Belize | Nicaragua | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.37 | 3.4 | 0.03 | Nicaragua |
| 1990s | 3.29 | 3.4 | 0.11 | Nicaragua |
| 2000s | 3.27 | 3.4 | 0.13 | Nicaragua |
| 2010s | 3.37 | 3.4 | 0.0333 | Nicaragua |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Belize or Nicaragua?
- Belize, at 3.4 against 3.4 in Nicaragua as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Belize and Nicaragua?
- 0, with Belize ahead.
- How many years of comparable data are there for Belize and Nicaragua?
- 39 years are reported by both, from 1980 to 2018.
- How do Belize and Nicaragua rank globally for statin use vs. average non-hdl cholesterol levels?
- Belize ranks 75th and Nicaragua ranks 75th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.